TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20035387

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation and new drug therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risk-adapted treatment approach
Number of subjects: 0
Study: 18565859

Group type: EXPERIMENTAL
Intervention: Rhythm control
Number of subjects: 1376

Group type: COMPARATOR
Intervention: Rate control
Number of subjects: 1376
Study: 11313177

Group type: EXPERIMENTAL
Intervention: Quality control of radical prostatectomy based on surgical parameters (surgical margins, postoperative PSA, urinary incontinence)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Number of radical prostatectomies performed per year
Number of subjects: 232
Study: 9165189

Group type: EXPERIMENTAL
Intervention: Intensive mode (IM) with 3 applications within a 2‐week period
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Monthly mode (MM) during a 3‐month period
Number of subjects: 88
Study: 8427957

Group type: EXPERIMENTAL
Intervention: Prednisone/Doxorubicin (regimen 1)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Teniposide/Cytarabine (regimen 2)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Overall event-free survival
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Age less than 10 years at initial diagnosis
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: White blood cell count less than 5,000/microL at relapse
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Duration of first remission greater than 54 months
Number of subjects: 105
Study: 3618289

Group type: EXPERIMENTAL
Intervention: Alprazolam (mean final dose: 3.05 mg)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Amitriptyline (mean final dose: 130 mg)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 81

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 81
Study: 29268139

Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m2
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Docetaxel 60 mg/m2 plus carboplatin AUC4
Number of subjects: 75
Study: 27643602

Group type: EXPERIMENTAL
Intervention: SMILE (Small Incision Lenticule Extraction)
Number of subjects: 200
Study: 26204994

Group type: EXPERIMENTAL
Intervention: Bright white-yellowish light therapy for half an hour every morning for 4 weeks
Number of subjects: 98

Group type: COMPARATOR
Intervention: Dim green light condition (control)
Number of subjects: 98
Study: 23569339

Group type: EXPERIMENTAL
Intervention: Olympus V-scope (VS)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Conventional ERCP
Number of subjects: 49
Study: 19891619

Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication review consultations
Number of subjects: 29
Study: 18816010

Group type: EXPERIMENTAL
Intervention: Individual cognitive-behavioral treatment (CBT)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral treatment (CBT)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 57
Study: 16600235

Group type: EXPERIMENTAL
Intervention: Past oral contraceptive use
Number of subjects: 672

Group type: COMPARATOR
Intervention: Non-prior users
Number of subjects: 672
Study: 12955552

Group type: EXPERIMENTAL
Intervention: Metoclopramide (MCP) 10 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 10811154

Group type: EXPERIMENTAL
Intervention: Resting positions (four randomized positions)
Number of subjects: 0
Study: 8822673

Group type: EXPERIMENTAL
Intervention: Diabetic neuropathic patients
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 19
Study: 1330398

Group type: EXPERIMENTAL
Intervention: Quinapril 20 mg administered at 8 AM
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Quinapril 20 mg administered at 10 PM
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Quinapril 20 mg administered once daily
Number of subjects: 18
Study: 31870749

Group type: EXPERIMENTAL
Intervention: Intravenous administration of tranexamic acid (TXA) 1000 mg 10 minutes before surgery
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (plain saline)
Number of subjects: 72
Study: 31350908

Group type: EXPERIMENTAL
Intervention: Dietary nitrate supplementation (12.8 mmol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-intensity exercise
Number of subjects: 0
Study: 29084397

Group type: EXPERIMENTAL
Intervention: In-centre nocturnal haemodialysis (INHD)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional haemodialysis (control)
Number of subjects: 25
Study: 27513234

Group type: EXPERIMENTAL
Intervention: Active group (P6 electrical stimulation with grade 3 strength)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham group (inactivated electrodes covered by silicone)
Number of subjects: 80
Study: 24717698

Group type: EXPERIMENTAL
Intervention: Palonosetron 0.0025 mg
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Palonosetron 0.0050 mg
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Palonosetron 0.0075 mg
Number of subjects: 286

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study: 22450972

Group type: EXPERIMENTAL
Intervention: Ceftolozane alone (single dose)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ceftolozane-tazobactam (single dose)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ceftolozane alone (multiple doses)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ceftolozane-tazobactam (multiple doses)
Number of subjects: 6
Study: 19222316

Group type: EXPERIMENTAL
Intervention: Imagery condition (imagining positively resolved auditory descriptions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Verbal condition (listening to the same events while thinking about their verbal meaning)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imagery condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Verbal conditions aimed to increase or reduce verbal comparisons
Number of subjects: 0
Study: 18283076

Group type: COMPARATOR
Intervention: Placebo warfarin dose modification schedules
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Warfarin treatment arm
Number of subjects: 569
Study: 15787083

Group type: EXPERIMENTAL
Intervention: Dual lumen catheters (DLCs)
Number of subjects: 473

Group type: COMPARATOR
Intervention: Triple lumen catheters (TLCs)
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 473
Study: 12592232

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/d)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 10226724

Group type: EXPERIMENTAL
Intervention: Composite resins
Number of subjects: 73

Group type: COMPARATOR
Intervention: Amalgam
Number of subjects: 73
Study: 9101948

Group type: EXPERIMENTAL
Intervention: Endoscopic extraperitoneal hernia repair (TEP)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Shouldice technique
Number of subjects: 224
Study: 1854110

Group type: EXPERIMENTAL
Intervention: Ranitidine plus triple therapy (2 g/d of tetracycline, 750 mg/d of metronidazole, and 5 or 8 bismuth subsalicylate tablets per day)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Ranitidine alone (300 mg/d)
Number of subjects: 105
Study: 6318304

Group type: EXPERIMENTAL
Intervention: mecillinam
Number of subjects: 74

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 74
Study: 30805706

Group type: EXPERIMENTAL
Intervention: TVT exact®
Number of subjects: 303

Group type: COMPARATOR
Intervention: RetroArc®
Number of subjects: 303
Study: 28355323

Group type: COMPARATOR
Intervention: Conventional physical therapy (CPT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Physical therapy based on reflex stimulation (RPT)
Number of subjects: 12
Study: 26914684

Group type: EXPERIMENTAL
Intervention: HILT plus exercise (HILT + EX)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo laser plus exercise (PL + EX)
Number of subjects: 60
Study: 24121806

Group type: EXPERIMENTAL
Intervention: Enclosed silver dressing (Mepilex Ag; Aquacel Ag)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical silver sulfadiazine (SSD)
Number of subjects: 0
Study: 22846195

Group type: EXPERIMENTAL
Intervention: Early ART (2-4 weeks after ATT)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Delayed ART (8-12 weeks after ATT)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 150
Study: 19459762

Group type: EXPERIMENTAL
Intervention: Humalog + 300 U of rHuPH20 (11.3 microg/mL)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Humulin R + 240 U of rHuPH20 (10 microg/mL)
Number of subjects: 26
Study: 17353259

Group type: EXPERIMENTAL
Intervention: Rivastigmine TID (3 times daily)
Number of subjects: 678

Group type: EXPERIMENTAL
Intervention: Rivastigmine BID (twice daily)
Number of subjects: 678

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 678
Study: 15451715

Group type: EXPERIMENTAL
Intervention: Home care services usage
Number of subjects: 1537

Group type: EXPERIMENTAL
Intervention: Predictors of home care service use
Number of subjects: 1537

Group type: EXPERIMENTAL
Intervention: Self-rated financial adequacy
Number of subjects: 1537
Study: 11394733

Group type: EXPERIMENTAL
Intervention: Extended-release oxybutynin 10 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Tolterodine 2 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Immediate-release oxybutynin 5 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 9699222

Group type: EXPERIMENTAL
Intervention: Capsule A (5 mg MT)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Capsule B (10 mg MT)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Capsule C (10 mg MT)
Number of subjects: 15
Study: 7989518

Group type: EXPERIMENTAL
Intervention: Assisted hatching with co-culture (AH+CC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Assisted hatching alone (AH-alone)
Number of subjects: 100
Study: 2524992

Group type: EXPERIMENTAL
Intervention: Baclofen, 60 mg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31733917

Group type: EXPERIMENTAL
Intervention: Super Skills for Life (SSL) intervention group
Number of subjects: 123

Group type: COMPARATOR
Intervention: Waiting-list control (WLC) group
Number of subjects: 123
Study: 29868869

Group type: EXPERIMENTAL
Intervention: TPW located behind the cashier (n = 80)
Number of subjects: 160

Group type: COMPARATOR
Intervention: TPW hidden behind an opaque wall (n = 80)
Number of subjects: 160
Study: 28277874

Group type: EXPERIMENTAL
Intervention: HL301 0.6 g/day
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: HL301 1.2 g/day
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: HL301 1.8 g/day
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: All HL301 treatment groups
Number of subjects: 160
Study: 25664620

Group type: EXPERIMENTAL
Intervention: Speech recognition intervention
Number of subjects: 1187

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1187
Study: 23466507

Group type: EXPERIMENTAL
Intervention: Modified unilateral laminotomy for bilateral decompression (M‐ULBD)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Conventional laminectomy
Number of subjects: 56
Study: 21680092

Group type: EXPERIMENTAL
Intervention: Self-management training (SMT)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Targeted self-management training (TSMT)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Continuous oral contraceptive therapy (COCT)
Number of subjects: 171
Study: 18455416

Group type: EXPERIMENTAL
Intervention: Radial artery
Number of subjects: 225

Group type: COMPARATOR
Intervention: Saphenous vein
Number of subjects: 225
Study: 16553952

Group type: EXPERIMENTAL
Intervention: W-BQ12 (12-item Well-being Questionnaire)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: GWBI (General Well-being Index)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: W-BQ12
Number of subjects: 157

Group type: COMPARATOR
Intervention: GWBI
Number of subjects: 157
Study: 12596107

Group type: EXPERIMENTAL
Intervention: Topical testosterone application (Testoviron, 2 mg/kg/wk for 3 weeks)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Intramuscular testosterone injection (same preparation, weekly for 3 weeks)
Number of subjects: 26
Study: 10509041

Group type: EXPERIMENTAL
Intervention: Epirubicin/paclitaxel combination plus G‐CSF
Number of subjects: 25
Study: 9069029

Group type: EXPERIMENTAL
Intervention: Health risk assessment with targeted follow-up
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 2071350

Group type: EXPERIMENTAL
Intervention: 750 mg ciprofloxacin 4 hr before surgery (group I)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 750 mg ciprofloxacin 8 hr before surgery (group II)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Two 750 mg doses of oral ciprofloxacin every 12 hr, last dose 12 hr before surgery (group III)
Number of subjects: 21
Study: 6343089

Group type: EXPERIMENTAL
Intervention: Mitomycin at 20 mg/20 ml instilled every 2 weeks for the first year and every 4 weeks for the second year starting 3‐4 weeks after TUR
Number of subjects: 58

Group type: COMPARATOR
Intervention: No further therapy (Control)
Number of subjects: 58
Study: 30553932

Group type: EXPERIMENTAL
Intervention: Supervised exercise physiotherapy
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Manual physiotherapy
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Combined exercise and manual physiotherapy
Number of subjects: 206

Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 206
Study: 30045594

Group type: EXPERIMENTAL
Intervention: Transforaminal (TF) epidural steroid injection
Number of subjects: 40

Group type: COMPARATOR
Intervention: Interlaminar (IL) epidural steroid injection
Number of subjects: 40
Study: 27825987

Group type: EXPERIMENTAL
Intervention: Bacillus subtilis CU1 (2 × 10^9 spores per day for 40 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26561622

Group type: EXPERIMENTAL
Intervention: +AA
Number of subjects: 62

Group type: COMPARATOR
Intervention: ‐AA
Number of subjects: 62
Study: 23138014

Group type: EXPERIMENTAL
Intervention: ivabradine (5 to 7.5mg bid)
Number of subjects: 854

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 854
Study: 21253715

Group type: EXPERIMENTAL
Intervention: Calcium plus vitamin D (CaD) supplementation
Number of subjects: 1970

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1970
Study: 18339093

Group type: EXPERIMENTAL
Intervention: Error prevention teaching procedure
Number of subjects: 2

Group type: COMPARATOR
Intervention: Error correction teaching procedure
Number of subjects: 2
Study: 16552809

Group type: EXPERIMENTAL
Intervention: Diuretics plus human albumin 25 g/wk in the first year and 25 g every two weeks thereafter (group 1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Diuretics alone (group 2)
Number of subjects: 100
Study: 12701663

Group type: EXPERIMENTAL
Intervention: CBT+TAU
Number of subjects: 144

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 144
Study: 11073753

Group type: EXPERIMENTAL
Intervention: Zinc gluconate (13.3 mg)
Number of subjects: 554

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Zinc acetate (5 or 11.5 mg)
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Zinc gluconate
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Zinc acetate
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: All treatments (including placebo)
Number of subjects: 554
Study: 9322140

Group type: EXPERIMENTAL
Intervention: T10B9.1A-31 (T10B9)
Number of subjects: 9

Group type: COMPARATOR
Intervention: OKT3
Number of subjects: 9
Study: 8250368

Group type: EXPERIMENTAL
Intervention: 1 g of cefapirine intravenously every eight hours, four times, starting at induction of anaesthesia
Number of subjects: 72
Study: 3957710

Group type: EXPERIMENTAL
Intervention: Retinyl palmitate, 8000 i.u. daily from 30 weeks gestation to term (N=14)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (N=15)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Non-Asian controls (N=21)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Asian women (N=23)
Number of subjects: 44
Study: 30316839

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (walking/jogging on a motor driven treadmill at 70% of age-predicted maximum heart rate, HR = 136.1 ± 11.1 bpm)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Active control (walking on the treadmill at 0.5 mph and 0% grade, HR = 92.0 ± 12.2 bpm)
Number of subjects: 41
Study: 27748551

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 25035748

Group type: EXPERIMENTAL
Intervention: Deliberate apprenticeship (DA) with senior residents
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control (unpaired students)
Number of subjects: 145
Study: 23075206

Group type: EXPERIMENTAL
Intervention: Permanent stress
Number of subjects: 7251

Group type: COMPARATOR
Intervention: Periodic stress
Number of subjects: 7251

Group type: COMPARATOR
Intervention: No stress
Number of subjects: 7251
Study: 20087334

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication
Number of subjects: 12
Study: 18209674

Group type: EXPERIMENTAL
Intervention: 20% mannitol solution (n = 10 patients)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 7.45% hypertonic saline solution (HSS) (n = 10 patients)
Number of subjects: 20
Study: 16803420

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 or 10 mg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Valsartan 80 or 160 mg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg, 10 mg, or 10 mg plus hydrochlorothiazide
Number of subjects: 20

Group type: COMPARATOR
Intervention: Valsartan 80 mg, 160 mg, or 160 mg plus hydrochlorothiazide
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Amlodipine and Valsartan
Number of subjects: 20
Study: 14763352

Group type: EXPERIMENTAL
Intervention: Misoprostol (800 micrograms/day)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPI)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: H2-receptor antagonists (H2-RA) at double-dose
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard doses of H2-RA
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 35
Study: 10982217

Group type: EXPERIMENTAL
Intervention: Antihistamine alone (n = 13)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Antihistamine in combination with intranasal corticosteroid (n = 13)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 26
Study: 8815985

Group type: EXPERIMENTAL
Intervention: Polyurethane (Pellethane)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Silicone (Silastic)
Number of subjects: 12
Study: 1406859

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 571

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 571
Study: 2877875

Group type: EXPERIMENTAL
Intervention: Ketamine (2 mg kg‐1) and alcuronium, supplemented by N2O‐O2 (Group KA)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ketamine (2 mg kg‐1) and alcuronium, supplemented by N2O‐O2 and 0.5% halothane (Group KAH)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Thiopentone and alcuronium, supplemented by N2O‐O2 and halothane (Control Group TAH)
Number of subjects: 25
Study: 29351961

Group type: EXPERIMENTAL
Intervention: REAL Diabetes intervention group (IG)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Attention control group (CG)
Number of subjects: 81
Study: 26955763

Group type: EXPERIMENTAL
Intervention: Primary Care Pathway for Childhood Asthma intervention (electronic guide and train-the-trainer education)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 25216543

Group type: EXPERIMENTAL
Intervention: Standard short infusion (1g imipenem/1g cilastatin over 30min three times daily)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Extended infusion (0.5g imipenem/0.5g cilastatin over 3h four times daily)
Number of subjects: 22
Study: 20686499

Group type: EXPERIMENTAL
Intervention: Olmesartan (10-40 mg) plus amlodipine (5 mg) for 8 weeks
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: Olmesartan (up-titrated to 20/5, 40/5 or 40/10 mg) plus amlodipine (5 mg)
Number of subjects: 755

Group type: COMPARATOR
Intervention: Amlodipine (5 mg) monotherapy
Number of subjects: 755
Study: 16162629

Group type: EXPERIMENTAL
Intervention: rescue percutaneous coronary intervention (rPCI) arm
Number of subjects: 307

Group type: COMPARATOR
Intervention: conservative arm
Number of subjects: 307
Study: 11959608

Group type: EXPERIMENTAL
Intervention: Amprenavir (1,200 mg; single dose) with grapefruit juice
Number of subjects: 12

Group type: COMPARATOR
Intervention: Amprenavir (1,200 mg; single dose) with water
Number of subjects: 12
Study: 9647606

Group type: EXPERIMENTAL
Intervention: Zafirlukast
Number of subjects: 0
Study: 8029794

Group type: EXPERIMENTAL
Intervention: 40 mg enoxaparin
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 1 mg/kg body weight of enoxaparin
Number of subjects: 36

Group type: COMPARATOR
Intervention: 5000 IU unfractionated heparin (UFH)
Number of subjects: 36
Study: 2563743

Group type: EXPERIMENTAL
Intervention: Loratadine, 10 mg once daily
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Terfenadine, 60 mg taken twice daily
Number of subjects: 228

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study: 1101903

Group type: EXPERIMENTAL
Intervention: Tolfenamic acid (Clotam)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Oxyphenbutazone
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 12423711

Group type: EXPERIMENTAL
Intervention: Glyburide
Number of subjects: 30

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 30
Study: 31323097

Group type: EXPERIMENTAL
Intervention: Computational observer analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased noise in the number of isomerizations of each cone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Human observers
Number of subjects: 0
Study: 30511679

Group type: EXPERIMENTAL
Intervention: Teriflunomide 7 mg
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Teriflunomide 14 mg
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148